Keep your eye on the prize

We’re switching from autologous to allogeneic serum eyedrops.

Lifeblood will be launching our new allogeneic serum eyedrops (AlloSED) product in 2026. Manufactured from the generous donations of our male Group AB donors and delivered directly, our new AlloSED product and service model makes these eyedrops more efficient to produce, and available to more patients nationally. 

AlloSED have been approved by both the Therapeutic Goods Administration and the National Blood Authority. They will replace our autologous product, for which we have now stopped taking orders.

Lifeblood will commence taking requests for eligible patients for AlloSED in November 2025, for delivery from March 2026. 

Important information for ophthalmologists is available here. 

Patients should contact their ophthalmologist in the first instance.